Skip to main content
 

ImaCor, Inc.

ImaCor, Inc.

ImaCor’s One Touch Hemodynamic Ultrasound combines imaging and monitoring in a portable package for ease-of-use by high acuity care teams, resulting in lifesaving course corrections in as much as 70% of patients vs standard of care. Used in over 20,000 patients with no complications, ImaCor’s miniaturized transesophageal ultrasound probe is FDA approved to be left in place for up to 72 hours, enabling direct visualization of cardiac filling and function over time. ImaCor’s image-sourced AI-automated measurements (clearance pending) provide ICU nurses One Touch preload and contractility data for rapid decision making, transforming care for sepsis, surgery, and cardiac support patients.

More News

  • Digital care in your pocket: The role of technology in exercise, fitness, prevention, and rehabilitation

  • The Heart of the Matter: Why Cardiovascular Disease Is Digital Health’s Next Frontier

  • New dietary guidance emphasizes 9 key steps for eating well to support heart health